DR. DEEPALI SINGHAL

Abstract

All patients who underwent uneventful phacoemulsification over 15 months were randomly assigned to receive topical nepafenac (0.1%) [96 eyes], bromfenac (0.07%) [93 eyes], preservative‐free ketorolac (0.4%) [94 eyes], nepafenac (0.3%) [96 eyes], or prednisolone acetate (1%) [91 eyes]. At 1 and 6 weeks, there was no significant difference in pain score, conjunctival hyperemia, AC cells, change in IOP, and BCVA between the prednisolone and the NSAIDs, though nepafenac 0.3% was most effective. At 6 weeks, there was no significant difference in the number of patients with subclinical CME in the prednisolone versus NSAIDs. The mean increase in CMT was significantly lower in nepafenac 0.3% than in prednisolone at 1 and 6 weeks. So, NSAIDs are comparable to prednisolone post uneventful phacoemulsification. However, nepafenac 0.3% is most comparable to prednisolone and more efficacious in reducing the incidence of CME.